November 19th, 2026What Venglustat’s Approval Means for Rare Disease DevelopersFDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.Read more
November 17th, 2026Giredestrant Takes ESR1 Breast Cancer Treatment Into Oral Solid DosesThe FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.Read more